GMP: Why Visual Traceability Has Become a De Facto Requirement

In the pharmaceutical and medical device industry, compliance with GMP (Good Manufacturing Practices) has never been just a formality.
But today, something has changed.

Until a few years ago, it was often enough to demonstrate documented controls and properly followed procedures. Now, customers, auditors, and regulatory authorities expect more: objective, digital, and immediately accessible evidence.

This is why visual traceability has effectively become a requirement.

From Paper Documentation to Digital Evidence

GMP requires every production phase to be:

  • controlled

  • documented

  • traceable

  • verifiable

Traditionally, this meant:

  • manual records

  • operator signatures

  • sampling inspections

  • paper archives or static files

Today, however, during an audit the question is no longer simply:

“Did you perform the inspection?” But rather “Can you prove it with objective, traceable data?”

The difference is substantial.

What Is Visual Traceability?

Visual traceability means associating each produced unit with:

  • inspection images

  • quality control data

  • labeling and serialization verification

  • timestamps and process parameters

Through AI-based computer vision systems, every unit can be:

  • inspected 100% in-line

  • digitally archived

  • linked to batch, shift, production line, and operator

You don’t just know that an inspection was performed. You can prove it.

Why It Has Become “De Facto Mandatory”

Formally, GMP does not always require automated vision systems.

But in practice:

  • customers demand increasingly detailed evidence

  • audits are more rigorous

  • tolerance for risk is minimal

  • recalls have devastating financial impacts

In this environment, relying solely on manual inspection exposes companies to unnecessary risk.

Visual traceability reduces:

  • subjectivity

  • human error

  • data loss

  • post-delivery disputes

It has become a competitive standard.

SMEs: Not Just for Large Corporations

Many SMEs think:

“This level of control is only for multinational companies.”

That is no longer the case.

Today’s AI vision solutions are:

  • modular

  • scalable

  • integrable into existing lines (retrofit)

  • economically sustainable

Most importantly, they allow SMEs to:

  • reduce audit preparation time

  • respond quickly to non-conformities

  • strengthen relationships with structured customers

For an SME, this means raising quality standards without increasing complexity.

The Real Advantage: Moving from Reactive to Preventive

With visual traceability, companies do not just record defects.

They can:

  • identify recurring patterns

  • link defects to process conditions

  • intervene before a non-conforming batch is produced

This transforms quality from a reactive function into a predictive system.

Audits, Recalls, and Responsibility

In the event of:

  • a customer complaint

  • a deviation

  • an extraordinary audit

  • an internal investigation

Being able to instantly access:

  • inspection images

  • quality control data

  • production history

makes the difference between controlled management and a critical situation.

Visual traceability becomes a protective shield.

Conclusion

In pharma and medical manufacturing, GMP compliance is no longer just about documentation. It is about demonstrating—through objective, traceable data—that every product has been properly inspected.

Visual traceability may not always be formally mandated. But in today’s market, it has become practically indispensable.

The real question is no longer:

“Do we really need it?” But 👉 If an unexpected audit occurred today, could you prove within minutes that every unit was properly inspected?

Want to know more? Contact us at info@metalya.it

Previous
Previous

AI Vision for the Inspection of Sterile Single-Use Devices

Next
Next

Sterility and Defects: How to Prevent an Error from Becoming a Recall